GRHL2 Expression Functions in Breast Cancer Aggressiveness and Could Serve As Prognostic and Diagnostic Biomarker for Breast Cancer

Overview

Journal Clin Med Insights Oncol

Publisher Sage Publications

Specialty Oncology

Date 2022 Jul 28

PMID 35898391

Authors

Xiaoyu Bai

Yue Li

Yanlei Li

Fan Li

Na Che

Chunsheng Ni

Nan Zhao

Xiulan Zhao

Tieju Liu

Affiliations

Soon will be listed here.

Abstract

Background: Breast cancer (BC) is the most frequent malignancy in women worldwide and the leading cause of female cancer-associated death in the world. Grainyhead-like 2 () is an important gene involved in human cancer progression. However, the role of GRHL2 in BC is unknown.

Methods: In this study, we used in vitro experiments to verify the role of expression in BC progression. We used 14 databases to analyse the expression level of GRHL2 in BC and its prognostic and diagnostic value. In addition, the correlation between GRHL2 expression and immune cell infiltration and DNA methylation was also analysed.

Results: At the cellular level, overexpression of induced E-cadherin expression in BC cells with a mesenchymal phenotype and resulted in a hybrid epithelial/mesenchymal (E/M) phenotype, which is more strongly correlated with tumour aggressiveness than a pure mesenchymal phenotype. Through analysis of various databases, we found that tumour tissue had a higher expression level of . High expression of was associated with worse prognosis of BC patients and indicated that GRHL2 had significant diagnostic value. Grainyhead-like 2 is also related to immune infiltration and regulated by DNA methylation. Furthermore, Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) analyses showed that -related signalling pathways in BC were related to tumour cell proliferation, invasion, and angiogenesis.

Conclusions: In summary, evidence indicates that can be used as a prognostic and diagnostic biomarker for BC.

Citing Articles

Custom target-sequencing in triple-negative and luminal breast cancer from young Brazilian patients.

Serio P, Saccaro D, de Gouvea A, Encinas G, Maistro S, Pereira G Clinics (Sao Paulo). 2024; 79:100479.

PMID: 39208653 PMC: 11399600. DOI: 10.1016/j.clinsp.2024.100479.

Elevated GRHL2 Imparts Plasticity in ER-Positive Breast Cancer Cells.

Zheng C, Allen K, Liu T, Solodin N, Meyer M, Salem K Cancers (Basel). 2024; 16(16).

PMID: 39199676 PMC: 11353109. DOI: 10.3390/cancers16162906.

RSRC2 Expression Inhibits Malignant Progression of Triple-Negative Breast Cancer by Transcriptionally Regulating SCIN Expression.

Zhao N, Ni C, Fan S, Che N, Li Y, Wang S Cancers (Basel). 2024; 16(1).

PMID: 38201443 PMC: 10778392. DOI: 10.3390/cancers16010015.

CHMP4A stimulates CD8+ T-lymphocyte infiltration and inhibits breast tumor growth via the LSD1/IFNβ axis.

Song S, Zhang D, Chen J, Qi L, Zhang M, Yang X Cancer Sci. 2023; 114(8):3162-3175.

PMID: 37198999 PMC: 10394147. DOI: 10.1111/cas.15844.

References

Huang Y, Tong Z, Chen K, Wang Y, Liu P, Gu L . Interpretation of breast cancer screening guideline for Chinese women. Cancer Biol Med. 2020; 16(4):825-835. PMC: 6936244. DOI: 10.20892/j.issn.2095-3941.2019.0322. View

Ali H, Provenzano E, Dawson S, Blows F, Liu B, Shah M . Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Ann Oncol. 2014; 25(8):1536-43. DOI: 10.1093/annonc/mdu191. View

Xiang X, Deng Z, Zhuang X, Ju S, Mu J, Jiang H . Grhl2 determines the epithelial phenotype of breast cancers and promotes tumor progression. PLoS One. 2013; 7(12):e50781. PMC: 3524252. DOI: 10.1371/journal.pone.0050781. View

Frisch S, Farris J, Pifer P . Roles of Grainyhead-like transcription factors in cancer. Oncogene. 2017; 36(44):6067-6073. DOI: 10.1038/onc.2017.178. View

Li Y, Sun R, Zhao X, Sun B . RUNX2 promotes malignant progression in gastric cancer by regulating COL1A1. Cancer Biomark. 2021; 31(3):227-238. DOI: 10.3233/CBM-200472. View

Lotter W, Diab A, Haslam B, Kim J, Grisot G, Wu E . Robust breast cancer detection in mammography and digital breast tomosynthesis using an annotation-efficient deep learning approach. Nat Med. 2021; 27(2):244-249. PMC: 9426656. DOI: 10.1038/s41591-020-01174-9. View

Zhang L, Wang W, Wang R, Zhang N, Shang H, Bi Y . Reshaping the Immune Microenvironment by Oncolytic Herpes Simplex Virus in Murine Pancreatic Ductal Adenocarcinoma. Mol Ther. 2020; 29(2):744-761. PMC: 7854309. DOI: 10.1016/j.ymthe.2020.10.027. View

Li B, Severson E, Pignon J, Zhao H, Li T, Novak J . Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol. 2016; 17(1):174. PMC: 4993001. DOI: 10.1186/s13059-016-1028-7. View

Xiong Y, Wei Y, Gu Y, Zhang S, Lyu J, Zhang B . DiseaseMeth version 2.0: a major expansion and update of the human disease methylation database. Nucleic Acids Res. 2016; 45(D1):D888-D895. PMC: 5210584. DOI: 10.1093/nar/gkw1123. View

10.

Emens L . Breast Cancer Immunotherapy: Facts and Hopes. Clin Cancer Res. 2017; 24(3):511-520. PMC: 5796849. DOI: 10.1158/1078-0432.CCR-16-3001. View

11.

Mlacki M, Kikulska A, Krzywinska E, Pawlak M, Wilanowski T . Recent discoveries concerning the involvement of transcription factors from the Grainyhead-like family in cancer. Exp Biol Med (Maywood). 2015; 240(11):1396-401. PMC: 4935299. DOI: 10.1177/1535370215588924. View

12.

Josefowicz S, Lu L, Rudensky A . Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol. 2012; 30:531-64. PMC: 6066374. DOI: 10.1146/annurev.immunol.25.022106.141623. View

13.

Topalian S, Drake C, Pardoll D . Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015; 27(4):450-61. PMC: 4400238. DOI: 10.1016/j.ccell.2015.03.001. View

14.

Modhukur V, Iljasenko T, Metsalu T, Lokk K, Laisk-Podar T, Vilo J . MethSurv: a web tool to perform multivariable survival analysis using DNA methylation data. Epigenomics. 2017; 10(3):277-288. DOI: 10.2217/epi-2017-0118. View

15.

Torres-Reyes L, Alvarado-Ruiz L, Pina-Sanchez P, Martinez-Silva M, Ramos-Solano M, Olimon-Andalon V . Expression of transcription factor grainyhead-like 2 is diminished in cervical cancer. Int J Clin Exp Pathol. 2015; 7(11):7409-18. PMC: 4270610. View

16.

Uhlen M, Fagerberg L, Hallstrom B, Lindskog C, Oksvold P, Mardinoglu A . Proteomics. Tissue-based map of the human proteome. Science. 2015; 347(6220):1260419. DOI: 10.1126/science.1260419. View

17.

Thege F, Gruber C, Cardle I, Cong S, Lannin T, Kirby B . anti-EGFR capture mitigates EMT- and chemoresistance-associated heterogeneity in a resistance-profiling CTC platform. Anal Biochem. 2019; 577:26-33. DOI: 10.1016/j.ab.2019.02.003. View

18.

Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin A, Kim S . The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012; 483(7391):603-7. PMC: 3320027. DOI: 10.1038/nature11003. View

19.

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

20.

Yang Z, Wu D, Chen Y, Min Z, Quan Y . GRHL2 inhibits colorectal cancer progression and metastasis via oppressing epithelial-mesenchymal transition. Cancer Biol Ther. 2019; 20(9):1195-1205. PMC: 6741563. DOI: 10.1080/15384047.2019.1599664. View